Biomarker-Guided Drug Development of YAP/TAZ-TEAD inhibitors
Time: 12:15 pm
day: Conference Day One
Details:
- SW-682: preclinical data for a novel TEAD inhibitor for Hippo-mutant cancers
- Overview of potential biomarkers for patient stratification, target engagement and molecular response
- Biomarkers for YAP activation as oncogenic driver or resistance mechanism to targeted therapies
